Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology
• Transplantation Medicine

Background:

• Invasive fungal disease (IFD) presents a significant threat to pediatric transplant recipients, contributing to substantial morbidity and mortality.
• The development of new antifungal medications is crucial for managing IFD in this vulnerable population.

Approach:

• This review synthesizes current data on novel antifungal agents, including their mechanisms of action and spectrum of activity.
• It specifically evaluates pediatric-specific data and clinical development stages for emerging antifungal drugs.
• The discussion includes key drug attributes and potential roles in pediatric transplant care.

Key Points:

• Novel antifungal agents like encochleated amphotericin B deoxycholate, fosmanogepix, ibrexafungerp, isavuconazole, olorofim, opelconazole, oteseconazole, and rezafungin are under development.
• Understanding their mechanisms, activity spectrum, and pediatric data is essential for clinical application.
• These agents represent a growing therapeutic arsenal against IFD in children.

Conclusions:

• Emerging antifungal agents hold promise for improving IFD management in pediatric transplant recipients.
• Further research and pediatric-specific trials are necessary to fully establish the role of these novel drugs.
• Optimizing antifungal strategies is critical for reducing IFD-related complications in this patient group.